Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
NCT07871409 on ClinicalTrials.gov · last registry update 2026-10-13
Registered but not yet open, with 230 participants planned. Due to report 16 June 2027. Sponsors move these dates routinely; any movement since this site started watching is listed below. maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Sponsor
- Amgen
- Sponsor type
- Industry
- Enrollment
- 230
- Started
- 2026-10-28
- Primary completion
- 2027-06-16 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-13 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home Administration
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.